Sichuan Biokin Pharmaceutical (SHA:688506) said its new drug application for innovative cancer treatment iza-bren has been accepted by China's medical products administrator.
The drug is intended for locally advanced or metastatic nasopharyngeal carcinoma that failed prior treatments, according to a Monday filing with the Shanghai bourse.
Shares of the pharmaceutical company were up 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments